Roche says FDA grants priority review for Tecentriq in stage III colon cancer, citing 36-month DFS of 86% vs 76% for standard therapy.
Roche reports that the FDA has granted priority review for Tecentriq in a specific stage III colon cancer indication, with a 36-month disease-free survival rate of 86% compared with 76% for standard therapy.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near US
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
DR Congo Ebola cases rise to 635, recoveries reach 30, health minister says. Eight new recoveries reported in Ituri province as contact tracing improves.
The number of confirmed Ebola cases in the Democratic Republic of the Congo has risen to 635 as of June 9, with 30 recoveries, Health Minister Roger Kamba said Wednesday.
Wall Street indexes fall more than 1%, hit by tech losses and Iran war worries
Wall Street indexes fell more than 1%, pressured by technology stocks and concerns over a potential conflict with Iran.
US and Iran exchange air strikes for second day; Trump vows more attacks unless Tehran agrees to peace deal immediately.
The United States and Iran traded air attacks for a second straight day, with President Trump vowing further strikes if Tehran does not immediately agree to a peace deal.
DOJ asks federal judge to dismiss criminal case against Turkish state-run lender Halkbank, citing no intention to prosecute
The US Department of Justice formally asked a federal judge to dismiss its criminal case against Halkbank, saying it has no intention of prosecuting the Turkish state-run lender.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.